Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China

Ejemplares similares

• Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
  por: Xichen Tong, et al.
  Publicado: (2026)
• Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
  por: Hirotaka Watada, et al.
  Publicado: (2024)
• Pharmacokinetic and pharmacodynamic properties of once‐weekly insulin icodec in individuals with type 1 diabetes
  por: Ulrike Hövelmann, et al.
  Publicado: (2024)
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant‐level analysis of the ONWARDS 1–5 trials
  por: Peter Rossing, et al.
  Publicado: (2025)
• Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c , BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5
  por: Alice Y. Y. Cheng, et al.
  Publicado: (2025)